{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699995829570176.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.jhep.2005.10.018"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0168827805006975?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0168827805006975?httpAccept=text/plain"}}],"dc:title":[{"@value":"Virologic response and resistance to adefovir in patients with chronic hepatitis B"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699995829570179","@type":"Researcher","foaf:name":[{"@value":"Scott K. Fung"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995829570176","@type":"Researcher","foaf:name":[{"@value":"Hee Bok Chae"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995829570177","@type":"Researcher","foaf:name":[{"@value":"Robert J. Fontana"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995829570178","@type":"Researcher","foaf:name":[{"@value":"Hari Conjeevaram"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995829570050","@type":"Researcher","foaf:name":[{"@value":"Jorge Marrero"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995829570049","@type":"Researcher","foaf:name":[{"@value":"Kelly Oberhelman"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995829570051","@type":"Researcher","foaf:name":[{"@value":"Munira Hussain"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995829570048","@type":"Researcher","foaf:name":[{"@value":"Anna S.F. Lok"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01688278"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/01688278"}],"prism:publicationName":[{"@value":"Journal of Hepatology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2006-02","prism:volume":"44","prism:number":"2","prism:startingPage":"283","prism:endingPage":"290"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0168827805006975?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0168827805006975?httpAccept=text/plain"}],"createdAt":"2005-11-16","modifiedAt":"2025-09-29","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002218199423872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140544000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical course and predictive factors of virological response in long‐term lamivudine plus adefovir dipivoxil combination therapy for lamivudine‐resistant chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204790550784","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of treatment for chronic hepatitis B using nucleos(t)ide analogues"},{"@language":"ja","@value":"核酸誘導体によるB型慢性肝炎治療の現状と課題"},{"@value":"Editorial 核酸誘導体によるB型慢性肝炎治療の現状と課題"},{"@language":"ja-Kana","@value":"Editorial カクサン ユウドウタイ ニ ヨル Bガタ マンセイ カンエン チリョウ ノ ゲンジョウ ト カダイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679846719360","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Overlap/Switch to Adefovir Monotherapy for Lamivudine-resistant Patients Who Responded to Combination Therapy: A Pilot Controlled Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679847528832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Rescue Therapy for Lamivudine-resistant Chronic Hepatitis B: Adefovir Monotherapy, Adefovir Plus Lamivudine or Entecavir Combination Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679849678208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hypophosphatemic Osteomalacia Due to Drug-induced Fanconi's Syndrome Associated with Adefovir Dipivoxil Treatment for Hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.jhep.2005.10.018"},{"@type":"CROSSREF","@value":"10.1111/j.1365-2893.2010.01301.x_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.49.3342_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.51.7329_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.2957/kanzo.47.499_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.1002/jmv.22025_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.53.1213_references_DOI_OJbBwMnkaX1dtRuMGHyACRpSzKK"}]}